Ann: AJM: Receivership Update, page-13

First 13 Last

Share
Profile

Follow
torval

694 Posts.

90

29/10/20

11:12

Post #: 48485355
Share

Originally posted by fugazied: ↑

That's why I am unsure about PLS pursuing this. Spodumene prices could remain low for a long time to come. It's a possibility. COVID is exploding in the US and EU with France and Germany about to re-enter lockdown. This could stifle the global economy, stifling transition to renewable/EVs and stifling SC6 price recoveries. There are also political factors, a Trump re-election could mean more chaos, fights with China, and promotion of fossil fuels.

While we have pushed our debt repayments back, they still remain. Management is looking at further dilution and a lot of cash to complete the deal, plus who knows how much to fix their operations. What happens if SC6 prices haven't returned by 2022? What if we are still selling at a loss? If the cash bleed continues for 12-24 months? PLS could be next on the chopping block.

So, the extra risk earns us what exactly? More spodumene when we've already got 30 years worth of the stuff? Very ambitious and a lot of risk is involved. I think the timing is bad, but I guess we'll see.

Expand

The benefits are the fact we are getting stage 2 without having to do any of the work.

More benefits include economies of scale, efficiencies that were already in place with AJM.Also our main competitor is gone so pricing is tighter.
It's 15% that could be taken out of the market if required. No one else is going to step up and produce at this low price, AJM only did because they were on their knees.

PLS Price at posting: 39.0¢ Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply